Evidence synthesis as the key to more coherent and efficient research

BMC Medical Research Methodology

Volumn 9, Issue 1, 2009, Pages

  Sutton, Alexander J ^a   Cooper, Nicola J ^a   Jones, David R ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL EVALUATION; CLINICAL PRACTICE; EVIDENCE BASED PRACTICE; INFORMATION SYSTEM; MEDICAL RESEARCH; PRACTICE GUIDELINE; PRODUCTIVITY; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL INFORMATICS; META ANALYSIS; METHODOLOGY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL;

EVIDENCE-BASED MEDICINE; HUMANS; MEDICAL INFORMATICS APPLICATIONS; META-ANALYSIS AS TOPIC; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 65649088642     PISSN: None     EISSN: 14712288     Source Type: Journal    
DOI: 10.1186/1471-2288-9-29     Document Type: Article

References (54)

1. Evidence-based medicine: what it is and what it isn't. DL Sackett WM Rosenberg JA Gray RB Haynes WS Richardson, BMJ 1996 312 71 72 8555924
2. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5. JPT Higgins S Green editors, The Cochrane Library Chichester, UK: John Wiley & Sons, Ltd 2005 3
3. Improving the quality of reporting of meta-analysis of randomised controlled trials: the QUOROM statement. D Moher DJ Cook S Eastwood I Olkin D Rennie, Onkologie 2000 23 6 597 602 11441269 (Pubitemid 32046061)
4. Doing new research? Don't forget the old. M Clarke, PLoS Medicine 2004 1 2 e35 15578106 (Pubitemid 40412706)
5. How useful are Cochrane reviews in identifying research needs? L Clarke M Clarke T Clarke, Journal of Health Services Research & Policy 2007 12 101 103 17407660 (Pubitemid 46733212)
6. Statistical and theoretical considerations in meta-analysis. I Olkin, J Clin Epidemiol 1995 48 133 146 7853039
7. Evidence-based sample size calculations based upon updated meta-analysis. AJ Sutton NJ Cooper DR Jones PC Lambert JR Thompson, Stat Med 2007 26 2479 2500 16981184 (Pubitemid 46784206)
8. How quickly do systematic reviews go out of date? A survival analysis. KG Shojania M Sampson MT Ansari J Jun S Doucette, Annals of Internal Medicine 2007 147 224 233 17638714
9. Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group. LA Stewart MJ Clarke, Stat Med 1995 14 2057 2079 8552887
10. A comparison of summary patient level covariates in meta-regression with individual patient data meta-analyses. P Lambert AJ Sutton KR Abrams DR Jones, Journal of Clinical Epidemiology 2002 55 86 94 11781126 (Pubitemid 34037039)
11. Covariate heterogeneity in meta-analysis: criteria for deciding between meta-regression and individual patient data. MC Simmonds JPT Higgins, Statistics in Medicine 2007 26 2982 2999 17195960 (Pubitemid 46939422)
12. Meta-analysis of individual- and aggregate-level data. AJ Sutton D Kendrick CAC Coupland, Statistics in Medicine 2008 27 651 669 17514698
13. Home safety education and provision of safety equipment for injury prevention. D Kendrick C Coupland C Mulvaney J Simpson SJ Smith, Cochrane Database of Systematic Reviews Wiley, Chichester 2007 CD005014
14. The miracle of DICE therapy for acute stroke: Fact or fictional product of subgroup analysis? CE Counsell MJ Clarke J Slattery PAG Sandercock, BMJ 1994 309 6970 1677 1681 7819982
15. Network meta-analysis for indirect treatment comparisons. T Lumley, Statistics in Medicine 2002 21 2313 2324 12210616
16. Combination of direct and indirect evidence in mixed treatment comparisons. G Lu AE Ades, Statistics in Medicine 2004 23 3105 3124 15449338 (Pubitemid 39334902)
17. Assessing evidence inconsistency in mixed treatment comparisons. G Lu AE Ades, Journal of the American Statistical Association 2006 101 447 459
18. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. DM Caldwell AE Ades JPT Higgins, BMJ 2005 331 897 900 16223826 (Pubitemid 41502718)
19. Mixed comparison of stroke prevention treatments in individuals with non-rheumatic atrial fibrillation. NJ Cooper AJ Sutton G Lu K Khunti, Archives of Internal Medicine 2006 166 1369 1275 (Pubitemid 43967578)
20. Multiple parameter evidence synthesis in epidemiology and medical decision-making: current approaches. A Ades AJ Sutton, Journal of the Royal Statistical Society Series A 2006 169 5 35
21. The validation of surrogate endpoints in meta-analyses of randomized experiments. M Buyse G Molenberghs T Burzykowski D Renard H Geys, Biostatistics 2000 1 49 67 12933525 (Pubitemid 33213521)
22. A chain of evidence with mixed comparisons: models for multi-parameter synthesis and consistency of evidence. AE Ades, Statistics in Medicine 2003 22 2995 3016 12973783 (Pubitemid 37160601)
23. Discussion sections in reports of controlled trials published in general medical journals. M Clarke P Alderson I Chalmers, JAMA 2002 287 2799 2801 12038916 (Pubitemid 34591967)
24. Putting clinical trials into context. C Young R Horton, Lancet 2005 366 9480 107 108 16005318 (Pubitemid 40991198)
25. The use of systematic reviews when designing new studies. NJ Cooper DR Jones AJ Sutton, Clinical Trials 2005 2 260 264 16279149 (Pubitemid 40910477)
26. Sifting the evidence what's wrong with significance tests? Another comment on the role of statistical methods. JAC Sterne G Davey Smith DR Cox, BMJ 2001 322 226 231 11159626
27. Trials to assess equivalence: the importance of rigorous methods. B Jones P Jarvis JA Lewis AF Ebbutt, BMJ 1996 313 36 39 8664772 (Pubitemid 26229889)
28. Prior distributions for the intracluster correlation coefficient, based on multiple previous estimates, and their application in cluster randomized trials. RM Turner SG Thompson DJ Spiegelhalter, Clinical Trials 2005 2 108 118 16279132 (Pubitemid 40637893)
29. Sample size calculations in randomised trials: mandatory and mystical. KF Schulz DA Grimes, Lancet 2005 365 9467 1348 1353 15823387 (Pubitemid 40501299)
30. Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis. JM Pogue S Yousuf, Controlled Clinical Trials 1997 18 580 593 9408720 (Pubitemid 27520846)
31. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Wetterslev K Thorlund J Brok C Gluud, Journal of Clinical Epidemiology 2008 61 64 75 18083463 (Pubitemid 350245732)
32. Adaptive group sequential designs for clinical trials: combining the advantages of adaptive and classical group sequential approaches. HH Muller H Schafer, Biometrics 2001 57 886 891 11550941 (Pubitemid 32801186)
33. Sample size calculations in clinical research. SC Chow J Shao H Wang, Chapman & Hall/CRC Biostatistics Boca Raton, Florida Second 2003
34. Measuring inconsistency in meta-analyses. JPT Higgins SG Thompson JJ Deeks DG Altman, BMJ 2003 327 557 560 12958120 (Pubitemid 37088507)
35. Explaining heterogeneity in meta-analysis: a comparison of methods. SG Thompson SJ Sharp, Stat Med 1999 18 2693 2708 10521860 (Pubitemid 29481404)
36. Being sceptical about meta-analyses: a Bayesian perspective on magnesium trials in myocardial infarction. JPT Higgins DJ Spiegelhalter, International Journal of Epidemiology 2002 31 96 104 11914302 (Pubitemid 34284908)
37. Lessons learned from a prospective meta-analysis. SE Margitic TM Morgan MA Sager CD Furberg, J Am Geriatr Soc 1995 43 435 439 7706636
38. Prospective meta-analysis of cholesterol-lowering studies: The Prospective Pravastatin Pooling project (PPP) and the Cholesterol Treatment Trialists (CTT) collaboration. RJ Simes, Am J Cardiol 1995 76 9 122C 126C 7572681
39. Preventing publication bias: registries and prospective meta-analysis. JA Berlin D Ghersi, Publication bias in meta-analysis: prevention, assessment and adjustments Chichester: Wiley, Rothstein HR, Sutton AJ, Borenstein M, 2005
40. Bayesian methods to improve sample size approximations. CH Schmid JC Cappelleri J Lau, Numerical Computer Methods Part D NY: Elsevier, Johnson ML, Brand L, 2004 383 406 427 (Pubitemid 38401799)
41. Modelling publication bias in meta-analysis: a review. AJ Sutton F Song SM Gilbody KR Abrams, Statistical methods in medical research 2000 9 421 445 11191259 (Pubitemid 32050882)
42. Adjusted likelihoods for synthesizing empirical evidence from studies that differ in quality and design: effects of environmental tobacco smoke. RL Wolpert K Mengersen, Statistical Science 2004 19 450 471 (Pubitemid 40465975)
43. Recursive cumulative meta-analysis: a diagnostic for the evolution of total randomized evidence from group and individual patient data. JPA Ioannidis DG Contopoulos-Ioannidis J Lau, J Clin Epidemiol 1999 52 281 291 10235168 (Pubitemid 29305300)
44. The interpretation of random-effects meta-analysis in decision models. AE Ades G Lu JPT Higgins, Medical Decision Making 2005 25 646 654 16282215 (Pubitemid 41667133)
45. Double-blinded RCT of warfarin vs. placebo in patients with nonrheumatic atrial fibrillation without prior embolic event. Study CAFA, Ann Intern Med 1991 115 818 822 1834003
46. Use of cumulative meta-analysis in the design, monitoring, and final analysis of a clinical trial: A case study. WG Henderson T Moritz S Goldman J Copeland G Sethi, Controlled Clin Trials 1995 16 331 341 8582151
47. Hierarchical models in generalised synthesis of evidence: an example based on studies of breast cancer screening. TC Prevost KR Abrams DR Jones, Statistics in Medicine 2000 19 3359 3376 11122501 (Pubitemid 32056690)
48. Bias modelling in evidence synthesis. RM Turner DJ Spiegelhalter GCS Smith SG Thompson, J R Stat Soc Ser A Stat Soc 2009 172 1 21 47 19381328
49. A Bayesian approach to evaluating net clinical beneft allowed for parameter uncertainty. AJ Sutton NJ Cooper KR Abrams PC Lambert DR Jones, Journal of Clinical Epidemiology 2005 58 26 40 15649668 (Pubitemid 40103532)
50. Benefits and harms associated with hormone replacement therapy: clinical decision analysis. C Minelli KR Abrams AJ Sutton NJ Cooper, BMJ 2004 328 371 375 14962874 (Pubitemid 38241183)
51. Comprehensive decision analytical modelling in economic evaluation: A Bayesian approach. NJ Cooper AJ Sutton KR Abrams D Turner A Wailoo, Health Economics 2004 13 203 226 14981647 (Pubitemid 38292479)
52. A rational framework for decision making by the National Institute For Clinical Excellence (NICE). K Claxton M Sculpher M Drummond, Lancet 2002 360 9334 711 715 12241891 (Pubitemid 35232343)
53. Bayesian approaches to the value of information: implications for the regulation of new pharmaceuticals. K Claxton, Health Economics 1999 8 269 274 10348422 (Pubitemid 29219092)
54. Expected value of sample information calculations in medical decision modeling. AE Ades G Lu K Claxton, Medical Decision Making 2004 24 207 227 15090106 (Pubitemid 38391940)